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Alzheimer’s disease (AD) is characterized by protein aggregates, i.e. senile plaques and neurofibrillary tangles. The
ubiquitin-proteasome system has been proposed a role in proteolytic removal of these protein aggregates. Ubiqui-
tin carboxy-terminal hydrolase L1 (UCHL1) is a de-ubiquitinating enzyme with important functions in recycling of
ubiquitin. The S18Y polymorphism of the UCHL1 gene confers protection against Parkinson’s disease. In this study,
the genotype and allele frequencies of the UCHL1 S18Y polymorphism were investigated in 452 AD patients and
234 control subjects, recruited from four memory clinics in Sweden. Using a binary logistic regression model
including UCHL1 allele A and APOE ε4 allele positivity, age and sex as covariates with AD diagnosis as dependent
variable, an adjusted OR of 0.82 ([95% CI 0.55-1.24], P = 0.35) was obtained for a positive UCHL1 allele A carrier sta-
tus. The present study thus do not support a protective effect of the UCHL1 S18Y polymorphism against AD.
Findings
Aggregation of aberrant proteins is a hallmark of several
neurodegenerative diseases, including Alzheimer’s( A D ) ,
Huntington’s (HD) and Parkinson’s (PD) diseases. In
this context, the ubiquitin-proteasome system (UPS) has
been ascribed a central role in preventing the formation
of pathological protein aggregates by proteolytic removal
of defect proteins [1]. Proteins destined for degradation
by the UPS are labelled with a 76-amino acid peptide,
ubiquitin, through a series of conjugation steps by the
E1, E2 and E3 enzymes respectively. There are also two
classes of de-ubiquitinating enzymes; the ubiquitin-spe-
cific processing proteases (UBPC) and the ubiquitin car-
boxy-terminal hydrolase family (UHC). For recent
reviews on the UPS, see [2,3]. Ubiquitin carboxy-term-
inal hydrolase L1 (UCHL1) is an isoform of the UHC
group, expressed mainly in neurons and testis/ovary.
However, UCHL1 has also been found in cells of the
human diffuse neuroendocrine system and is expressed
is several forms of cancer [4-6]. UCHL1 has an impor-
tant role in recycling of ubiquitin through hydrolysis of
peptide-ubiquitin bonds and processing of ubiquitin pre-
cursors, but it also possesses ubiquitin ligase activity [7].
Moreover, it has been shown that UCHL1 associates
with monoubiquitin and elongates its half-life, thus
ensuring stability of ubiquitin within neurons [8].
Several genetic variants of the UCHL1 g e n eh a v eb e e n
described; both those leading to gain-of-function and
those resulting in loss-of-function. The I93 M mutant
results in 50% reduced activity [9], whereas the S18Y
variant exhibits increased hydrolytic activity [10]. Other
studies showed comparable hydrolase activity of the
UCHL1 S18Y variant when compared to the wild type
enzyme, but a reduction in ligase activity [11]. It has
also been demonstrated that the UCHL1 S18Y poly-
morphism has a specific ability to act as a potent
antioxidant in neuronal cell culture systems [12].
A number of reports have demonstrated a protective
effect of the S18Y polymorphism against sporadic PD in
different populations [13-16], although conflicting data
exist [17]. As for AD, data on UCHL1 genotype frequen-
cies and its effect on risk of AD is scarce and conflicting
[18,19]. The purpose of this study was to investigate the
UCHL1 S18Y polymorphism in AD patients and con-
trols in the Swedish population. Given that we, for sub-
sets of the participants, have previously collected data
on levels of CSF biochemical markers and neuropatholo-
gical scores for AD, associations between the UCHL1
S18Y polymorphism and these variables could be inves-
tigated in addition to the genetic risk analysis.
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AD and 234 subjects without dementia, all of Swedish
nationality. The AD patients and control subjects were
recruited and diagnosed from four memory clinics in
Sweden; Malmö (371 patients, 48 controls), Huddinge
(52 patients, 70 controls), Göteborg/Mölndal (29
patients, 95 controls) and Linköping (21 controls). The
patients were invited to participate at their first visit to
the respective clinic, where they also gave their informed
consent. The control subjects were recruited by adver-
tisement in the local newspapers or at senior citizen
organization meetings. A few of these controls were
spouses or unrelated friends of the patients. The study
was approved by the local Ethical Commissions at the
respective academic center and the tenets of the
Declaration of Helsinki were followed. Parts of the AD
and the control groups in this work have also been
included in previous studies on other polymorphisms
[20,21].
All AD patients underwent clinical examination, neu-
ropsychological evaluations including Mini-Mental State
Examinaton (MMSE), computed tomography (CT) or
magnetic resonance imaging (MRI) of the brain and
routine blood analyses. The healthy elderly controls
were classified as non-demented on the basis of a struc-
tured interview performed by a research nurse that
included information on health history, lifestyle-related
variables and psychosocial situation. Only controls with
an MMSE score of at least 26 were included in the
study. In addition, 65 years was set as the youngest age
of controls for participation in the study.
Patients were clinically diagnosed with probable late-
onset AD according to the NINCDS-ADRDA criteria
[22] by a dementia investigation team that included spe-
cialists in geriatric medicine and psychiatry. To avoid
inclusion of cases with familial Alzheimer’s disease
(FAD) only patients 60 years of age or older were
included in the study. In addition, all patients were
questioned about their family history regarding AD and
those with suspect heredity were excluded. Individuals
with significant psychiatric or somatic diseases other
than AD were excluded. Data on CSF biomarkers,
including the concentrations of total-tau (T-tau), phos-
pho-tau181 (P-tau181) and Ab1-42 was available for 260 of
the AD patients and 117 of the controls. Neuropatholo-
gical diagnosis and scores based on senile plaques and
neurofibrillary tangles were available for 65 of the AD
patients and 80 of the controls. Genomic DNA was
extracted from whole blood samples and brain tissue
using standard methods. APOE (gene map locus
19q13.2) genotyping had previously been performed by
minisequencing, as described in detail [23].
The UCHL1 (gene map locus 4p14; [Entrez gene ID:
7345]) S18Y, 54C>A polymorphism (rs5030732) was
analyzed using the Dynamic Allele Specific Amplifica-
tion (DASH) tehnology as described earlier [24]. The
PCR were carried out with HotStarTaq DNA Polymer-
ase® (QIAGEN, Hilden, Germany) in a final volume of
25 μl, containing 5-20 ng of template DNA. Optimal
conditions were: 1 mM MgCl2, 0.2 mM dNTPs, 0.02 U
Taq polymerase, 0.16 pmol/μlo ft h ef o r w a r db i o t i n y -
lated primer (5’Biotin-GCCGCCTTGTCTCCTCTCAG-
CAG3’) and 0.78 pmol/μl of the reverse primer
(5’GTCACTGGCCTGCGACCCC3’), (Invitrogen, Pais-
ley, UK) in 1 × PCR buffer (Roche, Mannheim, Ger-
many). The cycling profile was: 15 min at 95°C, then 39
cycles: 30 sec at 95°C, 45 sec at 60°C, 45 sec at 72°C
and finally 10 min at 72°C. To identify UCHL1 alleles
the probe 5’GACAGAAACGCACTTGT-Rox3’ (MWG
Biotech, London, United Kingdom) was used. The accu-
racy of the DASH method was verified by DNA sequen-
cing of 15 individuals representing the different UCHL1
genotypes (five of each genotype).
Primary analyses compared differences between the AD
patients and control subjects regarding age, sex, MMSE
score, biochemical markers, neuropathological scores,
genotype and allele frequencies using Fisher’se x a c tc
2
test, t-test and Mann-Whitney U test. Secondary analysis
of UCHL1 allele A-carrier status was performed with a
binary logistic regression model with diagnosis (AD ver-
sus control) as dependent variable and allele positivity,
age, sex and APOE ε4 allele status as independent vari-
ables. Significance was set at P < 0.05. SPSS 16.0 (SPSS
Inc, Chicago, Il) was used as statistic software.
In the AD group the mean age was 76.2 (SD 6.4) years
(range 60-102 years) and 299 (66.2%) were women. In
the control group the mean age was 75.9 (SD 7.1) years
(range 65-94 years) and 127 (58.8%) were women. A
summary of demographic and clinical characteristics is
presented in table 1, including MMSE score, CSF bio-
markers, neuropathological score and APOE ε4 allele-
carrier status.
Genotype and allele frequencies for the UCHL1 S18Y
polymorphism are shown in table 2. There was a signifi-
cant overrepresentation of the heterozygous genotype
(AC) in the control group (p = 0.03). There were no sig-
nificant differences between the controls and the cases
with regard to the homozygous genotypes however, even
if the CC genotype was overrepresented among the AD
patients with a border-line p-value (0.054). In addition,
when analyzing UCHL1 allele A-carrier status (dominant
approach) a positive allele A-carrier status was slightly
overrepresented in the control group (p = 0.054). The
distributions of the UCHL1 genotypes were in Hardy-
Weinberg equilibrium for the control group (P =0 . 6 0 2
for AA, P =0 . 6 9 2f o rA Ca n dP = 0.846 for CC) as well
as for the AD group (P = 0.436 for AA, P =0 . 6 4 7f o r
AC and P = 0.825 for CC).
Zetterberg et al. Molecular Neurodegeneration 2010, 5:11
http://www.molecularneurodegeneration.com/content/5/1/11
Page 2 of 5Using a binary logistic regression model including
UCHL1 allele A and APOE ε4 allele positivity, age and
sex as covariates with AD diagnosis as dependent vari-
able, an adjusted OR of 0.82 ([95% CI 0.55-1.24], P =
0.35) was obtained for a positive UCHL1 allele A carrier
status (table 3). On the basis of previously reported
UCHL1 allele frequencies, a standardized difference of
0.29 was calculated [15]. This yielded a power of the
study of 96%, indicating that the lack of association was
not spurious. CSF T-tau, P-tau181 or Ab1-42 levels were
n o ta f f e c t e db yt h eUCHL1 S18Y polymorphism (Table
4). Neither did neuropathological scores of senile pla-
ques and neurofibrillary tangles exhibit any associations
with the UCHL1 polymorphism (Table 4). Further, we
compared the UCHL1 allele A-positivity for AD patients
and control subjects respectively between the different
centers and found no differences (not shown).
Aggregation of proteins is a major feature of several
neurodegenerative disorders, including Alzheimer’sd i s -
ease (AD). Several lines of evidence suggest that the
ubiquitin-proteasome system (UPS) is involved in the
pathogenesis of AD [1]. Accumulation of ubiquitin in
senile plaques and neurofibrillary tangles [25-28],
changes in proteasome subunit composition in AD
[29] and an association of AD with polymorphic var-
iants of UBQLN1, encoding for ubiquilin which is a
ubiquitin-like protein [30], are some of the signs point-
ing towards a role of the UPS in AD. Of special inter-
est is the finding that UCHL1 is oxidized in AD and
that it is down-regulated in affected brain areas of AD
patients [31,32]. Also interesting is the finding that
exogenous UCHL1 ameliorated b-amyloid-induced
synaptic and memory dysfunction in an AD mouse
model [33].
Table 1 Demographic, clinical and genetic characteristics of patients with AD and controls
Characteristic AD patients (n = 452) Controls (n = 234) P-value
Sex, f/m (%) 299/153 (66.2/33.8) 127/89 (58.8/41.2) 0.071*
n = 452 n = 216
Age, years, 76.2 ± 6.4 (60-102) 75.9 ± 7.1 (65-94) 0.215
†
Mean ± SD (range) n = 341 n = 216
MMSE score, Median (25
th – 75
th percentiles) 22 (19-25) n = 367 29 (29-30) n = 113 <0.001
‡
T-tau (pg/ml), Mean ± SD 621 ± 319 n = 260 376 ± 162 n = 117 <0.001
†
P-tau181 (pg/ml), Mean ± SD 76.9 ± 31.2 n = 260 63.3 ± 19.9 n = 91 <0.001
†
Ab1-42 (pg/ml), Mean ± SD 409 ± 100 n = 260 720 ± 200 n = 117 <0.001
†
SPs and NFTs score, Median (25
th – 75
thpercentiles) 7 (6-8.5) n = 65 1 (0-3) n = 80 <0.001
†
APOE ε4 allele-carriers n (%)
number of ε4 alleles:
0 128 (28.3) 156 (72.2) <0.001*
1 238 (52.7) 55 (25.5) <0.001*
2 86 (19.0) 5 (2.3) <0.001*
n = 452 n = 216
*Fisher’s Exact Test,
†Mann-Whitney U-test. AD = Alzheimer’s disease, SD = Standard Deviation, MMSE = Mini Mental State Examination, Ab = b-amyloid, SPs =
senile plaques, NFTs = neurofibrillary tangles
Table 2 UCHL1 genotype and allele frequencies in patients with AD and controls
UCHL1 genotype
frequencies, n (%)
AD patients (n = 452) Controls (n = 234) P-value*
AA 15 (3.3) 6 (2.6) 0.649
AC 112 (24.8) 77 (32.9) 0.030
CC 325 (71.9) 151 (64.5) 0.054
UCHL1 allele frequencies, n (%)
†
allele A 142 (15.7) 89 (19.0) 0.128
allele C 762 (84.3) 379 (81.0)
UCHL1 allele A-carrier n (%) 127 (28.1) 83 (35.5) 0.054
UCHL1 allele C-carrier n (%) 437 (96.7) 228 (97.4) 0.649
*Fisher’s Exact Test,
†There are two alleles per subject, yielding n = 904 for AD patients and n = 468 for controls. AD = Alzheimer’s disease.
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ciated with lower incidence of Parkinson’s disease
[13-16]. The mechanism for this protective effect is not
known, but it may be at least partially explained by the
increased antioxidative capacity demonstrated in neuro-
nal cells expressing the UCHL1 S18Y variant [12]. Little
is known about its effect on AD prevalence. A Chinese
study has demonstrated lower frequencies of the A allele
and the AA genotype in female AD patients as com-
pared to female controls [19]. However, a genetic study
in a Colombian population could not find an association
between UCHL1 genotypes and AD [18]. The number
of genome-wide association studies in the AD field has
increased rapidly; none of these has reported the
UCHL1 S18Y polymorphism among the significant
SNPs found however [34,35].
The allele and genotype frequencies of the UCHL1
S18Y polymorphism seen in this study are in accordance
with previous results in Swedish populations [13]. The
present study do not support a role of the UCHL1 S18Y
polymorphism AD however.
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